Madrigal Pharmaceuticals Inc. (MDGL)
$536.20
$0.93
(0.17%)
As on 12-Aug-2026 16:00EDT
Market cap
$11,784 Mln
Revenue (TTM)
$1,284 Mln
P/E Ratio
--
P/B Ratio
22.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-8.3
-
Debt to Equity
0.7
-
Book Value
$--
-
EPS
$-12.9
-
Face value
--
-
Shares outstanding
23,104,126
10 Years Aggregate
CFO
$-1,147.99 Mln
EBITDA
$-1,462.51 Mln
Net Profit
$-1,429.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Madrigal Pharmaceuticals (MDGL)
| -7.9 | -0.1 | 7.9 | 53.4 | 46.2 | 44.7 | 53.5 |
|
BSE Sensex*
| -7.9 | 0.5 | 4.6 | -2.8 | 6.1 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Madrigal Pharmaceuticals (MDGL)
| 88.7 | 33.0 | -20.3 | 242.5 | -23.8 | 22.0 | -19.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Madrigal Pharmaceuticals (MDGL)
|
536.2 | 11,784.0 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.7 |
| 87.3 | 12,381.0 | 669.5 | -320.0 | -0.8 | -68.2 | -- | 26.6 | |
| 84.5 | 8,920.5 | 42.2 | -501.6 | -1,217.0 | -45.9 | -- | 6.9 | |
| 75.6 | 10,421.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 50.4 | 13,397.6 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 101.8 | 12,231.4 | 1,663.7 | 413.6 | 18.8 | 430 | 36.2 | 45.0 | |
| 332.9 | 9,662.5 | 440.5 | 241.5 | 33.4 | 18.7 | 41 | 7.0 | |
| 597.0 | 16,486.6 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.4 | 37.6 | |
| 386.3 | 10,057.6 | 0.0 | -339.1 | -- | -30.6 | -- | 6.1 | |
| 152.0 | 9,439.0 | 282.0 | 82.9 | -28.6 | 11.4 | 143 | 11.2 |
Shareholding Pattern
View DetailsAbout Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor... beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. Read more
-
Founder, Chief Medical Officer, President of Research & Development and Director
Dr. Rebecca A. Taub M.D.
-
Founder, Chief Medical Officer, President of Research & Development and Director
Dr. Rebecca A. Taub M.D.
-
Headquarters
West Conshohocken, PA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Madrigal Pharmaceuticals (MDGL)
What is the current share price of Madrigal Pharmaceuticals Inc (MDGL) Today?
The share price of Madrigal Pharmaceuticals Inc (MDGL) is $536.20 (NASDAQ) as of 12-Aug-2026 16:00 EDT. Madrigal Pharmaceuticals Inc (MDGL) has given a return of 46.24% in the last 3 years.
What is the current PB & PE ratio of Madrigal Pharmaceuticals Inc (MDGL)?
Since, TTM earnings of Madrigal Pharmaceuticals Inc (MDGL) is negative, P/E ratio is not available.
The P/B ratio of Madrigal Pharmaceuticals Inc (MDGL) is 22.68 times as on 07-Aug-2026, a 326 premium to its peers’ median range of 5.32 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-45.32
|
21.68
|
|
2024
|
-14.52
|
8.97
|
|
2023
|
-12.24
|
11.28
|
|
2022
|
-16.94
|
25.35
|
|
2021
|
-6.00
|
7.38
|
What is the 52 Week High and Low of Madrigal Pharmaceuticals Inc (MDGL)?
The 52-week high and low of Madrigal Pharmaceuticals Inc (MDGL) are Rs 615.00 and Rs 348.88 as of 13-Aug-2026.
What is the market cap of Madrigal Pharmaceuticals Inc (MDGL)?
Madrigal Pharmaceuticals Inc (MDGL) has a market capitalisation of $ 11,784 Mln as on 07-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Madrigal Pharmaceuticals Inc (MDGL)?
Before investing in Madrigal Pharmaceuticals Inc (MDGL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.